ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting

    B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases

    Ilias Lazarou1, Axel Finckh2, Lara Fischer3, Camillo Ribi3, Joerg Seebach3 and Pierre A. Guerne2, 1University Hospitals of Geneva, Geneva, Switzerland, 2Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, 3Immunology, University Hospitals of Geneva, Geneva, Switzerland

    Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…
  • Abstract Number: 445 • 2012 ACR/ARHP Annual Meeting

    Combination of Intra-Articular Steroid Injection and Infliximab More Effective Than Infliximab in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, x Ray Reader Blinded Study

    Kensuke Kume1, Kanzo Amano1, Susumu Yamada1, Kazuhiko Hatta2, Kuniki Amano3, Hiroyuki Ohta4 and Noriko Kuwaba5, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2Rheumatology, Hatta Clinic, Kure, Japan, 3Rheumatology, Sky Clinic, Hiroshima, Japan, 4Medical Research, hiroshima clinic, Hiroshima, Japan, 5Medical Research, Sanki Clinical Link, Hiroshima, Japan

    Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, recent publications described rapid radiographic progression (RRP) existed despite initial biologics and methotrexate…
  • Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting

    Antibodies to Citrullinated Peptides in Tuberculosis

    Isabella Lima1, Rodrigo Oliveira2, Ajax Atta2, Samyra Marchi3, Lúcio Barbosa3, Eliana Reis3, Mitermayer G. Reis3 and Mittermayer Santiago4, 1Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, 2Universidade Federal da Bahia, Salvador, Brazil, 3Fundação Oswaldo Cruz, Salvador, Brazil, 4Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…
  • Abstract Number: 178 • 2012 ACR/ARHP Annual Meeting

    Intravenous Immunoglobulin in Parvovirus B19 Mediated Pure Red Cell Aplasia: A Retrospective Study in 10 Patients and a Review of 123 Cases

    Yoann Crabol, Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    Background/Purpose: The efficacy of intravenous immunoglobulin (IVIg) therapy in patients with pure red cell aplasia (PRCA) related to human parvovirus B19 (HPV-B19) infection is mainly…
  • Abstract Number: 2543 • 2012 ACR/ARHP Annual Meeting

    Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents

    Jeffrey R. Curtis1, Shuo Yang2, Nivedita M. Patkar3, Lang Chen4, Jasvinder A. Singh5, Grant W. Cannon6, Ted R. Mikuls7, Elizabeth S. Delzell8, Kenneth G. Saag9, Monika M. Safford10, Scott DuVall11, Kimberly Alexander12, Pavel Napalkov12, Aaron Kamauu13 and John Baddley14, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, 4Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Department of Medicine, University of Alabama, Tuscaloosa, AL, 6Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, 7Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 8Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 9Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, 10Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, 11VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 12Epidemiology, Genentech, Inc., South San Francisco, CA, 13Anolinx, Bountiful, UT, 14Medicine, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Risks of hospitalized infections for newer biologic agents have not been well characterized compared to risks for anti-TNF therapy. Purpose: To compare the risk…
  • Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting

    How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study

    Hayato Yamazaki1, Ryoko Sakai1, Ryuji Koike2, Yasunari Miyazaki3, Michi Tanaka1, Toshihiro Nanki1, Kaori Watanabe1, Shinsuke Yasuda4, Takashi Kurita5, Yuko Kaneko6, Yoshiya Tanaka7, Yasuhiko Nishioka8, Yoshinari Takasaki9, Kenji Nagasaka10, Koichi Amano11, Shigeto Tohma12, Makoto Dohi13, Takahiko Sugihara14, Haruhito Sugiyama15, Yasushi Kawaguchi16, Naohiko Inase17, Sae Ochi18, Hiroyuki Hagiyama19, Nobuyuki Miyasaka20 and Masayoshi Harigai21, 1Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, 2Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, 4Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 5Department of Medicine II, Hokkaido University, Sapporo, Japan, 6Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, 7The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 8Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, 9Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 10Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, 11Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 12Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, 13Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 14Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 15Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, 16Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 17Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, 18Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, 19Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, 20Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 21Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…
  • Abstract Number: 2452 • 2012 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis-Associated PTPN22 Modulates Toll-Like Receptor-Mediated, Type 1 Interferon-Dependent Innate Immunoregulation

    Yaya Wang1, Stephanie Stanford2, Wenbo Zhou3, Jennifer L. Auger4, Genhong Cheng5, Amanda Campbell6, Fernanda M. Shoyama1, Henry H. Balfour Jr.7, Andrew C. Chan8, Bryce A. Binstadt4, Nunzio Bottini6 and Erik J. Peterson3, 1Department of Medicine, University of Minnesota, Minneapolis, MN, 2Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3University of Minnesota, Minneapolis, MN, 4Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, 5University of California, Los Angeles, Los Angeles, CA, 6La Jolla Institute for Allergy and Immunology, La Jolla, CA, 7University of Minnesota, Minneapolis, 8Immunology, Genentech Inc, South San Francisco, CA

    Background/Purpose: A coding polymorphism (C1858T) in PTPN22 is strongly associated with risk of Rheumatoid Arthritis (RA) and other autoimmune diseases. PTPN22 encodes Lymphoid Phosphatase (Lyp);…
  • Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting

    Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients

    Pierre Charles1, Antoine Néel2, Nathalie Tieulié3, Arnaud Hot4, Grégory Pugnet5, Olivier Decaux6, Isabelle Marie7, Mehdi Khellaf8, Jean-Emmanuel Kahn9, Alexandre Karras10, Jean-Marc Ziza11, Christophe Deligny12, Colas Tchérakian13 and Loic Guillevin14, 1Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 2Internal Medicine, Nantes University Hospital, Nantes, France, 3CHU Nice, Nice, France, 4Internal Medicine, Edouard Herriot University Hospital, Lyon, France, 5Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, 6Department of Internal Medicine, Rennes University Hospital, Rennes, France, 7Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 8Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 9Internal Medicine, Foch Hospital, Suresnes, France, 10Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 11Rheumatology, Croix Saint Simon Hospital, Paris, France, 12Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 13Service de pneumologie, hôpital Foch, Suresnes, France, 14Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…
  • Abstract Number: 1999 • 2012 ACR/ARHP Annual Meeting

    Immunogenicity and Safety of Two Doses of Influenza A H1N1⁄2009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old

    Guilherme Trudes1, Nadia E. Aikawa2, Lucia M. Campos3, Rosa M.R. Pereira4, Julio C. B. Moraes5, Ana Cristina Ribeiro6, Joao Miraglia7, Maria do Carmo S. Timenetsky8, Eloisa Bonfa4 and Clovis Artur Silva9, 1Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2Rheumatology, University of São Paulo, Sao Paulo, Brazil, 3Pediatric Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, 4Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 5Rheumatology Divison, University of Sao Paulo, Sao Paulo, Brazil, 6Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 7Instituto Butantan, Fundação Butantan, São Paulo, Brazil, 8Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 9Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: In 2010 the Advisory Committee on Immunization Practices from the CDC recommended that all children should receive the trivalent seasonal influenza vaccine containing the…
  • Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting

    Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials

    Sima Ahadieh1, Tina Checchio1, Thomas Tensfeldt1, Jonathan French2, Sriram Krishnaswami1, Richard Riese3, Sujatha Menon1, Mary G. Boy1 and Jamie L. Geier4, 1Pfizer Inc., Groton, CT, 2Metrum Research Institute, Tariffville, CT, 3Pfizer Inc, Groton, CT, 4Epidemiology, Pfizer Inc., New York, NY

    Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
  • Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting

    Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors

    Catrina B. Scherrer1, Anne AF Mannion2, Diego Kyburz3, Markus Vogt4 and Ines A. Kramers-de Quervain1, 1Rheumatology, Schulthess Clinic, Zürich, Switzerland, 2Research Department, Schulthess Clinic, Zürich, Switzerland, 3Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, 4Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland

    Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
  • Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting

    Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up

    Renata Baronaite Hansen1 and Søren Jacobsen2, 1Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, 2Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…
  • Abstract Number: 1424 • 2012 ACR/ARHP Annual Meeting

    Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology)

    José M. Pego-Reigosa1, Íñigo Rúa-Figueroa2, Francisco J. López-Longo3, María Galindo4, Jaime Calvo-Alén5, Alejandro Olivé6, Loreto Horcada7, Esther Uriarte8, Eva Tomero9, Ana Sánchez-Atrio10, Carlos Montilla11, José Rosas12, Antonio Fernández-Nebro13, Paloma Vela14, Mercedes Freire15, Lucía Silva16, Elvira Díez-Álvarez17, Carlos Marras18, Antonio Zea19, Javier Narváez20, Jose Luis Marenco21, Monica Fernández de Castro22, Olaia Fernánde-Berrizbeitia23, Marian Gantes24 and Celia Erausquin25, 1Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 2Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, 3Hospital Gregorio Marañón, Madrid, Spain, 4Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, 5Reumatología, Hospital Sierrallana, Torrelavega, Spain, 6Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 7Reumatología, Hospital de Navarra, Spain, 8Reumatología, Hospital de Donosti, Donosti, Spain, 9Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 10Reumatología, Hospital Príncipe de Asturias, Madrid, Spain, 11Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, 12Reumatología, Hospital de Marina Baixa, Alicante, Spain, 13Reumatología, Hospital Carlos Haya, Malaga, Spain, 14Reumatología, Hospital General de Alicante, Alicante, Spain, 15Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, 16Rheumatology, Hospital de Guadalajara, Guadalajara, Spain, 17Reumatología, Hospital de León, León, Spain, 18Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 19Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, 20Reumatología, Hospital de Bellvitge, Barcelona, Spain, 21Rheumatology, Hospital de Valme, Seville, Spain, 22Hospital Puerta del Hierro, Madrid, Spain, 23Reumatología, Hospital de Basurto, Basurto, Spain, 24Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, 25Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain

    Background/Purpose:  Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Immunosuppression, comorbidities, and the disease itself makes patients with SLE…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology